188 related articles for article (PubMed ID: 17295682)
1. Expression of neuroendocrine markers in non-small cell lung cancer.
Sørhaug S; Steinshamn S; Haaverstad R; Nordrum IS; Martinsen TC; Waldum HL
APMIS; 2007 Feb; 115(2):152-63. PubMed ID: 17295682
[TBL] [Abstract][Full Text] [Related]
2. Neuroendocrine differentiation in non-small cell lung cancer and its relation to prognosis and therapy.
Howe MC; Chapman A; Kerr K; Dougal M; Anderson H; Hasleton PS
Histopathology; 2005 Feb; 46(2):195-201. PubMed ID: 15693892
[TBL] [Abstract][Full Text] [Related]
3. Chromogranin A gene expression in non-small cell lung carcinomas.
Abbona G; Papotti M; Viberti L; Macrĭ L; Stella A; Bussolati G
J Pathol; 1998 Oct; 186(2):151-6. PubMed ID: 9924430
[TBL] [Abstract][Full Text] [Related]
4. [Detection of neuroendocrine differentiation in NSCLC and its clinical significance].
Ouyang N; Chen G; Ding J
Zhonghua Jie He He Hu Xi Za Zhi; 2001 Feb; 24(2):90-2. PubMed ID: 11802946
[TBL] [Abstract][Full Text] [Related]
5. [Multidrug resistance and its relationship with neuroendocrine differentiation in non-small cell lung carcinoma].
Yu SP; Xiong YY; Tian SF
Zhonghua Jie He He Hu Xi Za Zhi; 2003 Mar; 26(3):165-8. PubMed ID: 12816683
[TBL] [Abstract][Full Text] [Related]
6. Neuroendocrine differentiation in stage D2 prostate cancers.
Kamiya N; Suzuki H; Kawamura K; Imamoto T; Naya Y; Tochigi N; Kakuta Y; Yamaguchi K; Ishikura H; Ichikawa T
Int J Urol; 2008 May; 15(5):423-8. PubMed ID: 18452460
[TBL] [Abstract][Full Text] [Related]
7. Secretagogin is a new neuroendocrine marker in the human prostate.
Adolf K; Wagner L; Bergh A; Stattin P; Ottosen P; Borre M; Birkenkamp-Demtröder K; Orntoft TF; Tørring N
Prostate; 2007 Apr; 67(5):472-84. PubMed ID: 17285592
[TBL] [Abstract][Full Text] [Related]
8. Nonsmall cell lung carcinoma with neuroendocrine differentiation--an entity of no clinical or prognostic significance.
Ionescu DN; Treaba D; Gilks CB; Leung S; Renouf D; Laskin J; Wood-Baker R; Gown AM
Am J Surg Pathol; 2007 Jan; 31(1):26-32. PubMed ID: 17197916
[TBL] [Abstract][Full Text] [Related]
9. NCAM (neural cell adhesion molecules) expression in malignant mesotheliomas.
Lantuéjoul S; Laverrière MH; Sturm N; Moro D; Frey G; Brambilla C; Brambilla E
Hum Pathol; 2000 Apr; 31(4):415-21. PubMed ID: 10821486
[TBL] [Abstract][Full Text] [Related]
10. Neuroendocrine differentiation in colorectal carcinomas.
Syversen U; Halvorsen T; Mårvik R; Waldum HL
Eur J Gastroenterol Hepatol; 1995 Jul; 7(7):667-74. PubMed ID: 8590163
[TBL] [Abstract][Full Text] [Related]
11. Neuroendocrine differentiation as an indicator of chemosensitivity and prognosis in nonsmall cell lung cancer.
Petrović M; Baskić D; Banković D; Ilić N
Biomarkers; 2011 Jun; 16(4):311-20. PubMed ID: 21595568
[TBL] [Abstract][Full Text] [Related]
12. Expression of neuron-specific enolase, chromogranin A, synaptophysin and Leu-7 in lung cancer cell lines.
Poola I; Graziano SL
J Exp Clin Cancer Res; 1998 Jun; 17(2):165-73. PubMed ID: 9700577
[TBL] [Abstract][Full Text] [Related]
13. Neuroendocrine cells in pancreatic duct adenocarcinoma: an immunohistochemical study.
Linder S; Myrvold K; Falkmer UG; Qvigstad G; Waldum HL; Falkmer SE
J Exp Clin Cancer Res; 2006 Jun; 25(2):213-21. PubMed ID: 16918133
[TBL] [Abstract][Full Text] [Related]
14. Immunoreactivity for epithelial and neuroendocrine antibodies are useful in the differential diagnosis of lung carcinomas.
Lyda MH; Weiss LM
Hum Pathol; 2000 Aug; 31(8):980-7. PubMed ID: 10987260
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of circulating chromogranin A and soluble tumor necrosis factor receptors in advanced nonsmall cell lung cancer.
Gregorc V; Spreafico A; Floriani I; Colombo B; Ludovini V; Pistola L; Bellezza G; Viganò MG; Villa E; Corti A
Cancer; 2007 Aug; 110(4):845-53. PubMed ID: 17599769
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of elevated serum chromogranin A levels.
Syversen U; Ramstad H; Gamme K; Qvigstad G; Falkmer S; Waldum HL
Scand J Gastroenterol; 2004 Oct; 39(10):969-73. PubMed ID: 15513336
[TBL] [Abstract][Full Text] [Related]
17. Heterogeneity of so-called neuroendocrine lung tumors.
Yesner R
Exp Mol Pathol; 2001 Jun; 70(3):179-82. PubMed ID: 11417996
[TBL] [Abstract][Full Text] [Related]
18. Neuroendocrine differentiation in poorly differentiated lung carcinomas: a light microscopic and immunohistologic study.
Visscher DW; Zarbo RJ; Trojanowski JQ; Sakr W; Crissman JD
Mod Pathol; 1990 Jul; 3(4):508-12. PubMed ID: 2170973
[TBL] [Abstract][Full Text] [Related]
19. Neuroendocrine lung structures and tumours: immunohistochemical study by specific markers.
Mosca L; Barbareschi M; Mauri MF; Munguia-Barrera J; Frigo B; Muscarà M; Valentini L; Mariscotti C
Histol Histopathol; 1988 Oct; 3(4):367-76. PubMed ID: 2980246
[TBL] [Abstract][Full Text] [Related]
20. Microtubule-associated protein-2: a new sensitive and specific marker for pulmonary carcinoid tumor and small cell carcinoma.
Liu Y; Sturgis CD; Grzybicki DM; Jasnosz KM; Olson PR; Tong M; Dabbs DD; Raab SS; Silverman JF
Mod Pathol; 2001 Sep; 14(9):880-5. PubMed ID: 11557784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
